<DOC>
	<DOCNO>NCT00061919</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy carboplatin etoposide use different way stop tumor cell divide stop grow die . Thalidomide may stop growth cancer stop blood flow tumor . It yet know combination chemotherapy effective without thalidomide treat small cell lung cancer . PURPOSE : This randomized phase III trial study carboplatin , etoposide , thalidomide see well work compare carboplatin etoposide treat patient limited- extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Carboplatin Etoposide With Without Thalidomide Treating Patients With Limited-Stage Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival patient limited extensive stage small cell lung cancer treat carboplatin etoposide v without thalidomide . - Compare time disease progression patient treat regimen . - Compare toxicity regimens patient . - Compare response rate patient treat regimen . - Compare quality life patient treat regimen . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord disease stage ( limited v extensive ) , ECOG performance status ( 0 1 v 2 ) , alkaline phosphatase ( great 1.5 time upper limit normal [ ULN ] v great 1.5 time ULN ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive carboplatin IV 30 minute day 1 etoposide* IV 1-2 hour day 1 2 orally day 3 . Patients also receive oral thalidomide daily begin day 1 . - Arm II : Patients receive carboplatin etoposide arm I oral placebo daily begin day 1 . NOTE : *Patients unable receive etoposide IV day 2 may receive oral etoposide day 2 3 . In arm , chemotherapy ( carboplatin etoposide ) repeat every 3 week 6 course . Patients receive thalidomide placebo continuously 2 year . Treatment continue absence disease progression unacceptable toxicity . Patients experience disease progression may continue receive thalidomide placebo provide patient clinically symptomatically stable . Quality life assess baseline , course chemotherapy , 3-4 week completion chemotherapy , 6 , 12 , 18 , 24 month . Patients follow every 2 month 2 year completion chemotherapy every 3 month thereafter . Peer Reviewed Funded Endorsed Cancer Research UK PROJECTED ACCRUAL : A total 372 patient ( 186 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer Limited extensive stage disease No symptomatic brain metastasis require immediate radiotherapy PATIENT CHARACTERISTICS : Age Over 18 Performance status ECOG 03 Life expectancy At least 8 week Hematopoietic Not specify Hepatic Not specify Renal Ethylenediamine tetraacetic acid ( EDTA ) clearance great 60 mL/min OR Creatinine clearance great 50 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use 2 effective method contraception ( include 1 highly effective method 1 barrier method ) 4 week study completion No prior malignancy within past 3 year except nonmelanoma skin cancer early cervical cancer No significant medical condition laboratory find would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics No prior radiotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>limited stage small cell lung cancer</keyword>
</DOC>